ASTH

⬣ Investigation

Healthcare

Astrana Health, Inc.

Securities Investigation

Stock dropped 9.02% on September 17, 2026

Investigation in Progress — No Complaint Filed Yet

BG&G is actively investigating potential securities fraud claims against Astrana Health, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.

Why Is Astrana Health, Inc. (ASTH) Under Investigation?

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Astrana Health, Inc. (“Astrana” or “the Company”) (NASDAQ: ASTH). Investors who purchased Astrana securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Astrana has violated federal securities laws.

What Potential Securities Violations Is BG&G Investigating?

On September 17, 2026, Glass House Research published a short report alleging that Astrana’s growth relies on aggressive acquisitions and subjective management estimates rather than organic expansion, as well as citing concerns over a $545 million related-party loan and 2027 Medicare regulatory exposure. Following publication of the report, Astrana’s stock price dropped $3.40 per share, or 9.02%, to close at $34.30 on September 17, 2026.

What Should Astrana Health, Inc. (ASTH) Investors Do?

If you are aware of any facts relating to this investigation or purchased Astrana securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

How Is Astrana Health, Inc. (NASDAQ: ASTH) Stock Trading Today?

How Does BG&G Help Investors in Securities Fraud Investigations?

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”
— Peretz Bronstein, Founding Partner